Pancreatic Cancer Research

ResearcherUniversity of BonnNo recent work listed

Felix Meissner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1000-7989; OpenAlex author ID A5073970595. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

  1. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Last author DOI 10.1038/s41467-023-38171-8↗
  2. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan J. Swietlik · 2 shared papers, 2022–2023 · strength 0.27
  2. Stefanie Bärthel · 2 shared papers, 2022–2023 · strength 0.27
  3. Chiara Falcomatà · 2 shared papers, 2022–2023 · strength 0.27
  4. Dieter Saur · 2 shared papers, 2022–2023 · strength 0.27
  5. Constantin Schmitt · 1 shared paper, 2022 · strength 0.10
  6. Christian Schneeweis · 1 shared paper, 2022 · strength 0.10
  7. Woo Hyun Paik · 1 shared paper, 2022 · strength 0.10
  8. Maximilian Reichert · 1 shared paper, 2022 · strength 0.10
  9. Bernhard Küster · 1 shared paper, 2022 · strength 0.10
  10. Roland Rad · 1 shared paper, 2022 · strength 0.10
  11. Günter Schneider · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.